Online Rx Medz – FDA Warning Letter, Mar 1, 2026

On April 1, 2026, the FDA issued a warning letter to Online Rx Medz after reviewing their website and identifying the illegal sale of misbranded and unapproved new drugs. The agency found that the company was distributing high-risk medications, including opioids like Oxycodone 80mg, benzodiazepines such as Xanax 2mg, and Schedule II stimulants like Adderall 30mg, to U.S. consumers. These activities violate the Federal Food, Drug, and Cosmetic Act by introducing unapproved drugs into interstate commerce and failing to require valid prescriptions from licensed healthcare providers. The FDA emphasized that selling these medications without professional supervision poses severe public health risks, including potential addiction, overdose, and death, particularly given the ongoing opioid epidemic. Furthermore, the products lack the safety and efficacy assurances provided by the standard regulatory approval process. Online Rx Medz is required to immediately cease the sale of these unapproved and misbranded medications. The company must provide a written response to the FDA within 15 working days detailing the specific steps taken to address the violations and prevent their recurrence. Failure to comply may result in legal action, such as product seizure or court-ordered injunctions.